** Shares of biotech firm Aligos Therapeutics ALGS.O rise 3.8% to $27 premarket
** ALGS says it is raising $105 million in a private placement financing
** Co is selling ~2.1 million shares of common stock along with warrants to purchase up to ~2 million additional shares at a combined purchase price of $26.0825/shr
** Combined purchase price is at a 0.2% premium to the stock's last close
** Co says the funding will be used to start a mid-stage trial for ALG-000184, a treatment for chronic hepatitis B virus infection
** Co says the funding will extend its cash runway into the H2 of 2026
** Co has 3.6 million outstanding shares, with market cap of $93.4 million - LSEG data
** Jefferies and Piper Sandler are acting as placement agents
** ALGS shares more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.